The FDA cleared an updated algorithm for a hybrid closed-loop insulin delivery system that permits users to set a lower ...

Insulet PODD continues to gain on solid prospects in the diabetes market. The company is progressing well with respect to its four-pillar strategy. Yet, its heavy reliance on the Omnipod System and a ...

Insulet Corporation PODD recently received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new ...

Insulet anticipates that the Omnipod 5 algorithm update will launch in the US in H1 2026. The company highlighted that the ...

Insulet Corporation (NASDAQ: PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with DexCom Inc's (NASDAQ: DXCM) G6 ...

Insulet Corporation is a paid sponsor of The Morning Blend. According to the American Diabetes Association (ADA), more than 39 million Americans have diabetes. Of those, nearly 1.9 million Americans ...

Insulet PODD delivered outstanding first-quarter performance, fueled by the rollout of the new Omnipod 5, which has been on fire since regulatory approval was received last fall. Though management ...

On Sep 18, we issued an updated research report on Insulet Corporation PODD. Although the company’s achievement of two milestones with respect to expansion of Omnipod’s market reach makes us ...

LONDON--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...